Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
May 25, 2022

EMA grants orphan drug designation to Cornerstone Pharmaceuticals’ CPI-613 (devimistat)

Cornerstone Pharmaceuticals has announced that the European Medicines Agency (EMA) has granted orphan drug designation (ODD) to CPI-613 (devimistat) to treat advanced unresectable biliary tract cancer.

Image: Biliary tract cancer, which is also called as cholangiocarcinoma, is an extremely rare and hard to treat cancer. Credit: Nephron/commons.wikimedia.org.